ClinicalTrials.gg

Program

Gallium-68

Also written as “[68Ga]Ga-OncoACP3”, “Bombesin (68Ga) labeled (BAY86-7548)” and “[68Ga]Ga DOTA-5G”.

In Novartis's pipeline, Radioligand therapy target HER2. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Renal Cell · Urinary Bladder Neoplasms, led by 11 companies.

Furthest: phase 3, since Dec 15, 202217 company-led studies, 9 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen40 open or runningphase 1since Dec 15, 2022Dec 15, 2022none ahead
Novartis31 open or runningphase 3since Jan 26, 2024Mar 26, 2018Jan 26, 2029phase 1 · NCT07117214
Lantheus21 open or runningphase 3since Sep 4, 2026Sep 17, 2010Sep 30, 2029phase 3 · NCT07831824
Antaros Medical11 open or runningearly phase 1since Aug 14, 2024Aug 14, 2024none ahead
Bracco11 open or runningphase 2since Jun 30, 2026Jun 30, 2026Feb 2028phase 2 · NCT07702292
GE Healthcare11 open or runningphase 3since Oct 9, 2025Oct 9, 2025Jun 2029phase 3 · NCT07219238
Lumara Bio Oncologics11 open or runningphase 2since Dec 21, 2022Dec 21, 2022Jun 2027phase 2 · NCT05706129
Lumina Pharmaceuticals11 open or runningearly phase 1since Aug 19, 2026Aug 19, 2026Sep 1, 2027early phase 1 · NCT07781852
Luminance Biosciences11 open or runningphase 1since Oct 29, 2026Oct 29, 2026Dec 31, 2027phase 1 · NCT07915297
Sanofi10 open or runningphase 1since Nov 16, 2017Nov 16, 2017none ahead
SmartNuclide Biopharma11 open or runningearly phase 1since Oct 10, 2024Oct 10, 2024none ahead

Also a collaborator on its studies: medpace-inc and fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 17, 2010.

  1. Mar 26, 2018Novartis's first study: phase 2 study in Prostatic NeoplasmsNew to NovartisNovartis · NCT03490032 · 30 enrolled · United States
  2. Dec 15, 2022Philogen's first study: phase 1 study in Breast NeoplasmsNew to PhilogenPhilogen · NCT05784597 · 18 enrolled · Italy
  3. Dec 21, 2022Lumara Bio Oncologics's first study: phase 2 study in Carcinoma, Renal CellNew to Lumara Bio OncologicsLumara Bio Oncologics · NCT05706129 · 270 planned · Australia, France
  4. Jan 26, 2024Phase 3 study in HypersensitivityNovartis · NCT06240741 · 71 enrolled · Japan
  5. Aug 14, 2024Antaros Medical's first study: early phase 1 study in Crohn DiseaseNew to Antaros MedicalAntaros Medical · NCT06562361 · 30 planned · Sweden
  6. Oct 10, 2024SmartNuclide Biopharma's first study: early phase 1 study in Adenocarcinoma of the StomachNew to SmartNuclide BiopharmaSmartNuclide Biopharma · NCT06646783 · 28 planned · China
  7. Feb 17, 20252 phase 1 studiesPhilogen · NCT06840548, NCT06840535
  8. Jul 22, 2025Phase 1 study in Breast NeoplasmsNovartis · NCT07117214 · 36 planned · Netherlands
  9. Oct 9, 2025GE Healthcare's first study: phase 3 study in Colorectal NeoplasmsNew to GE HealthcareGE Healthcare · NCT07219238 · 175 planned · United States, Sweden
  10. May 6, 2026Phase 1 study in Prostatic NeoplasmsPhilogen · NCT07600554 · 20 enrolled · Italy
  11. Jun 30, 2026Bracco's first study: phase 2 study in Colorectal NeoplasmsNew to BraccoBracco · NCT07702292 · 71 planned · Italy, Netherlands
  12. Aug 19, 2026Lumina Pharmaceuticals's first study: early phase 1 study in Urinary Bladder NeoplasmsNew to Lumina PharmaceuticalsLumina Pharmaceuticals · NCT07781852 · 40 planned · United States
  13. Sep 4, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedLantheus · NCT07831824 · 408 planned · United States
  14. Oct 29, 2026Luminance Biosciences's first study: phase 1 study in Breast NeoplasmsNew to Luminance BiosciencesLuminance Biosciences · NCT07915297 · 10 planned · Australia

Ahead

  1. Jun 2027Primary completion: phase 2 study in Carcinoma, Renal CellLumara Bio Oncologics · NCT05706129
  2. Sep 1, 2027Primary completion: early phase 1 study in Urinary Bladder NeoplasmsLumina Pharmaceuticals · NCT07781852
  3. Dec 31, 2027Primary completion: phase 1 study in Breast NeoplasmsLuminance Biosciences · NCT07915297
  4. Feb 2028Primary completion: phase 2 study in Colorectal NeoplasmsBracco · NCT07702292

TargetBeta

“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07915297Breast Neoplasms · Australia1Not yet recruitingLuminance BiosciencesDec 31, 202710
NCT07831824Prostatic Neoplasms · United States3RecruitingLantheusSep 30, 2029408
NCT07781852Urinary Bladder Neoplasms · United StatesEarly 1Not yet recruitingLumina PharmaceuticalsSep 1, 202740
NCT07702292Colorectal Neoplasms · Italy, Netherlands2RecruitingBraccoFeb 202871
NCT07600554Prostatic Neoplasms · Italy1CompletedPhilogenOct 22, 202620
NCT07219238Colorectal Neoplasms · United States, Sweden3RecruitingGE HealthcareJun 2029175
NCT07117214Breast Neoplasms · Netherlands1RecruitingNovartisJan 26, 202936
NCT06840548Carcinoma, Renal Cell · Italy1CompletedPhilogenNov 28, 202520
NCT06840535Prostatic Neoplasms · Italy1CompletedPhilogenOct 3, 202520
NCT06646783Adenocarcinoma of the Stomach · ChinaEarly 1Not yet recruitingSmartNuclide BiopharmaOct 20, 202528
NCT06562361Crohn Disease · SwedenEarly 1RecruitingAntaros MedicalDec 202530
NCT06240741Hypersensitivity · Japan3CompletedNovartisDec 27, 202471
NCT05706129Carcinoma, Renal Cell · Australia, France2RecruitingLumara Bio OncologicsJun 2027270
NCT05784597Breast Neoplasms · Italy1CompletedPhilogenOct 21, 202418
NCT03490032Prostatic Neoplasms · United States2CompletedNovartisAug 20, 201930
NCT03350191Diabetes Mellitus, Type 2 · Sweden1CompletedSanofiJun 7, 201813
NCT01205321Neoplasms · Finland, Germany, Switzerland1CompletedLantheusNov 201119

How it is read

Names in the registry

  • “[68Ga]Ga-OncoACP3”, 2 entries
  • “Bombesin (68Ga) labeled (BAY86-7548)”, 2 entries
  • “[68Ga]Ga DOTA-5G”, 1 entry
  • “[68Ga]-LNTH-2401”, 1 entry
  • “[68Ga]BED003”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.